Mineralys Therapeutics (MLYS) insider reports option, RSU grants and transfers

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. director and more than 10% owner Brian Taylor Slingsby reported equity awards and related transfers on February 19, 2026. He received 8,300 stock options and 6,200 restricted stock units (RSUs) at an exercise/award price of $0.00 per share.

The RSUs give a contingent right to one common share each and vest in one annual installment after the grant date, while the stock options vest in 12 substantially equal monthly installments following the grant date. Certain options and RSUs were transferred under an option transfer agreement to Catalys Pacific Fund, LP, and some securities are held of record by that fund.

Catalys Pacific Fund, LP’s general partner is Catalys Pacific Fund GP, LP, whose general partner is Catalys Pacific, LLC. These entities and Brian Taylor Slingsby may be deemed to share voting and investment power over shares held by the fund, but each disclaims beneficial ownership except to the extent of any pecuniary interest.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Slingsby Brian Taylor

Role Director, 10% Owner

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	8,300	$0.00	--
Other	Stock Option	8,300	$0.00	--
Other	Stock Option	8,300	$0.00	--
Grant/Award	Common Stock	6,200	$0.00	--
Other	Common Stock	6,200	$0.00	--
Other	Common Stock	6,200	$0.00	--

Holdings After Transaction: Stock Option — 8,300 shares (Direct); Stock Option — 8,300 shares (Indirect, See footnote); Common Stock — 6,200 shares (Direct); Common Stock — 7,910,038 shares (Indirect, See footnote)

Footnotes (1)

1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant. Represents stock options or RSUs transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP. Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein. The stock option vests in 12 substantially equal monthly installments following the date of grant.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 02/20/2026 - 07:47 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Slingsby Brian Taylor

(Last) (First) (Middle)

1700 WESTLAKE AVE. N, SUITE 200

THINKSPACE

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/19/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/19/2026		A		6,200(1)	A	$0	6,200	D
Common Stock	02/19/2026		J(2)		6,200(1)	D	$0	0	D
Common Stock	02/19/2026		J(2)		6,200(1)	A	$0	7,910,038	I	See footnote(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$28.06	02/19/2026		A		8,300		(4)	02/19/2036	Common Stock	8,300	$0	8,300	D
Stock Option	$28.06	02/19/2026		J(2)			8,300	(4)	02/19/2036	Common Stock	8,300	$0	0	D
Stock Option	$28.06	02/19/2026		J(2)		8,300		(4)	02/19/2036	Common Stock	8,300	$0	8,300	I	See footnote(3)

Explanation of Responses:

1. Restricted Stock Units (RSUs) are granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting of these RSUs in one annual installment following the date of grant.

2. Represents stock options or RSUs transferred pursuant to an option transfer agreement between the Reporting Person and Catalys Pacific Fund, LP.

3. Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

4. The stock option vests in 12 substantially equal monthly installments following the date of grant.

Remarks:

	Catalys Pacific Fund, LP, By: Catalys Pacific Fund GP, LP, its General Partner, By: Catalys Pacific, LLC, its General Partner, By: Brian Taylor Slingsby, its Managing Partner, By: /s/ Adam Levy, Attorney-in-fact	02/20/2026
	Brian Taylor Slingsby by: /s/ Adam Levy, Attorney-in-fact	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Mineralys Therapeutics (MLYS) disclose in this Form 4 for Brian Taylor Slingsby?

The filing shows Brian Taylor Slingsby received stock options and RSUs and reported related transfers. These equity awards were granted at $0.00 per share and include both directly held securities and positions associated with Catalys Pacific Fund, LP.

How many options and RSUs did Brian Taylor Slingsby receive from Mineralys Therapeutics (MLYS)?

He received 8,300 stock options and 6,200 restricted stock units. Each RSU represents a contingent right to one share of Mineralys Therapeutics common stock, subject to vesting conditions described in the disclosure for the grant date.

What are the vesting terms of the Mineralys Therapeutics (MLYS) RSUs and stock options reported?

The RSUs vest in one annual installment after the grant date. The stock option award vests in 12 substantially equal monthly installments following the date of grant, spreading option vesting across the first year after issuance.

How is Catalys Pacific Fund, LP involved in the Mineralys Therapeutics (MLYS) insider transactions?

Some options and RSUs were transferred under an option transfer agreement to Catalys Pacific Fund, LP. The fund also holds certain securities of record, with related entities and Brian Taylor Slingsby potentially sharing voting and investment power over those holdings.

Does Brian Taylor Slingsby fully own the Mineralys Therapeutics (MLYS) shares held by Catalys Pacific Fund, LP?

The disclosure states Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power, but each disclaims beneficial ownership except to the extent of any pecuniary interest in those securities.

Were the Mineralys Therapeutics (MLYS) equity awards to Brian Taylor Slingsby purchased for cash?

No cash purchase is indicated. The stock options and RSUs were granted for no additional cash consideration, meaning they were issued as equity compensation rather than bought in an open-market or private cash transaction.